SB-659032
104623
Phase 1 small_molecule completed
Quick answer
SB-659032 for Atherosclerosis is a Phase 1 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline
- Indication
- Atherosclerosis
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed